GlaxoSmithKline 4Q Revenues: $9.9 billion (-12%) 4Q Earnings: $1.7 billion (-58%) FY Revenues: $38.0 billion (-9%) FY Earnings: $4.7 billion (-47%) Comments: Pharmaceutical sales were $8.1 billion in the quarter down 12%. Respiratory sales were $2.7 billion, down 16% impacted by continued price and contracting pressures. Advair sales were $1.8 billion, down 22%. Vaccine sales were $1.3 billion down 19% impacted primarily by lower sales of Boostrix, impacted by supply constraints. Fluarix, F...